3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
3
Other hematologic neoplasm
3
Lymphoid
3
Dermatologic
3
Sarcoma
2
Myeloid
2
Thoracic
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Classical hematology
1
CNS
1
Breast
1
Conditions
Glioblastoma
22
Brain Neoplasms
16
Central Nervous System Neoplasms
13
Glioma
9
Gliosarcoma
8
Neuroblastoma
7
Astrocytoma
7
Neoplasms
6
Recurrence
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Melanoma
3
Lymphoma
3
Lung Neoplasms
3
Testicular Neoplasms
2
Sarcoma
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neoplasm Metastasis
2
Meningeal Carcinomatosis
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Interventions
liposomal amphotericin B
2
Thiotepa
2
Psychiatric Rehabilitation
2
Melphalan
2
Fentanyl
2
Early Intervention, Educational
2
Caspofungin
2
sargramostim
1
Whole-Body Irradiation
1
Therapeutics
1
Rituximab
1
Radiotherapy
1
Quality of Life
1
Positron-Emission Tomography
1
Pentetic Acid
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Oxycodone
1
Morphine
1
Molecular Diagnostic Techniques
1
Minocycline
1
Methotrexate
1
Methadone
1
Immunotherapy
1
Heparin
1
Fluorescent Antibody Technique
1
Etoposide
1
Drug Therapy
1
Cyclophosphamide
1
Ciprofloxacin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
Drug Therapy
×
CNS
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled